---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015733"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:47:38.183996+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q1 net loss $67M; cash $668M; two Phase 1 trials ongoing

## Summary
- GAAP net loss of $67.0M for Q1 2023, compared to $68.1M in Q1 2022; non-GAAP net loss $44.8M vs $50.0M.
- Cash, equivalents and marketable securities of $668.0M as of March 31, 2023; cash runway into 2026.
- Revenue $0.1M, down from $0.6M due to termination of GSK collaboration in December 2022.
- Two Phase 1 trials (LYL797 CAR-T and LYL845 TIL) recruiting at 14 US sites; initial clinical data expected in 2024.
- LYL119 IND submission expected in first half of 2024; abstract at ASGCT May 2023.

## SEC filing metadata
- accession: 0001628280-23-015733
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/lyel-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015733
- JSON: https://secwatch.observer/filing/0001628280-23-015733.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015733.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.1 million, net income $67.0 million net loss.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $0.1 million
  - Net income: $67.0 million net loss
  - Result: reported results
  source text: First Quarter Financial Results Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022. Non‐GAAP net loss, which excludes non-cash stock-based compensation, non‐cash expenses related to the change in the estimated fair value of success payment liabilities and certain non-cash investment gains and charges, was $44.8 million for the first quarter ended March 31, 2023, compared to $50.0 million for the same period in 2022. Revenue • Revenue was $0.1 million for the first quarter ended March 31, 2023 compared to $0.6 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828023015733/0001628280-23-015733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.